A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. (Q37763117)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

4 February 2020

main subject

1 reference

1 reference

peginterferon alfa-2b

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Jeremy Jones

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Pharmacoeconomics & Outcomes Research

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

577-595

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Interferon for interferon naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Empirically calibrated model of hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

A comparison of fibrosis progression in chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.577

21 January 2018

Identifiers

DOI

10.1586/14737167.7.6.577

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20528320%20AND%20SRC:MED&resulttype=core&format=json